NO995695L - Substituted pyrazoles as p38 kinase inhibitors - Google Patents

Substituted pyrazoles as p38 kinase inhibitors Download PDF

Info

Publication number
NO995695L
NO995695L NO995695A NO995695A NO995695L NO 995695 L NO995695 L NO 995695L NO 995695 A NO995695 A NO 995695A NO 995695 A NO995695 A NO 995695A NO 995695 L NO995695 L NO 995695L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
substituted pyrazoles
pyrazoles
substituted
kinase
Prior art date
Application number
NO995695A
Other languages
Norwegian (no)
Other versions
NO995695D0 (en
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Joyce Zuowu Crich
Rajesh Devraj
Daniel Flynn
Lifeng Geng
Gunnar J Hanson
Francis J Koszyk
Shuyuan Liao
Richard Allen Partis
Shashidar N Rao
Shaun Raj Selness
Michael S South
Michael Allan Stealey
Richard M Weier
Xiangdong Xu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO995695D0 publication Critical patent/NO995695D0/en
Publication of NO995695L publication Critical patent/NO995695L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Description

En klasse av pyrazolderivater beskrives for anvendelse ved behandling av p3 8 kinase-medierte forstyrrelser. Forbindel-ser av spesiell interesse defineres ved formel I A class of pyrazole derivatives is described for use in the treatment of p3 8 kinase-mediated disorders. Compounds of particular interest are defined by formula I

hvorR<1>,R<2>,R<3>og R<4>har betydningene som angis i beskri-velsen . where R<1>, R<2>, R<3> and R<4> have the meanings given in the description.

NO995695A 1997-05-22 1999-11-19 Substituted pyrazoles as p38 kinase inhibitors NO995695L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
NO995695D0 NO995695D0 (en) 1999-11-19
NO995695L true NO995695L (en) 2000-01-21

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995695A NO995695L (en) 1997-05-22 1999-11-19 Substituted pyrazoles as p38 kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1000055A1 (en)
JP (1) JP2002508754A (en)
KR (1) KR20010012854A (en)
CN (1) CN1264377A (en)
AP (1) AP1246A (en)
AU (1) AU754830C (en)
BG (1) BG64313B1 (en)
BR (1) BR9809147A (en)
CA (1) CA2291115A1 (en)
EA (1) EA003925B1 (en)
EE (1) EE9900527A (en)
GE (1) GEP20033053B (en)
HU (1) HUP0001880A3 (en)
ID (1) ID22982A (en)
IL (1) IL132991A (en)
IS (1) IS5257A (en)
NO (1) NO995695L (en)
NZ (1) NZ501112A (en)
OA (1) OA12981A (en)
PL (1) PL337020A1 (en)
SK (1) SK157899A3 (en)
TR (1) TR200000235T2 (en)
WO (1) WO1998052940A1 (en)
ZA (1) ZA984358B (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (en) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1119254A4 (en) 1998-10-07 2004-05-12 Smithkline Beecham Corp Novel treatment for stroke management
CA2355075C (en) 1998-12-16 2009-12-08 Aventis Pharma Limited Heteroaryl-cyclic acetals
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
CN1326848C (en) * 1998-12-25 2007-07-18 帝国脏器制药株式会社 Aminopyrazole derivatives
EP1173169B1 (en) 1999-03-26 2010-05-12 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
CA2375986C (en) 1999-06-03 2009-12-08 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AR032130A1 (en) * 1999-08-13 2003-10-29 Vertex Pharma AN INHIBITOR COMPOUND OF PROTEIN KINASES, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND A METHOD TO TREAT AFFECTIONS WITH SUCH COMPOUND
AU7922100A (en) * 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
EP1309592B9 (en) 2000-08-14 2007-02-28 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical Jnk inhibitor
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
SK287857B6 (en) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AU2002330096B2 (en) 2001-09-25 2007-11-08 Pharmacia Corporation Process for making substituted pyrazoles
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
AU2003237446A1 (en) * 2002-06-05 2003-12-22 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
PL377848A1 (en) 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2576297C (en) 2004-08-12 2011-01-25 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
CA2591912C (en) 2004-12-28 2013-06-25 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazole derivatives
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
ES2396251T3 (en) 2006-06-28 2013-02-20 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
KR20090031721A (en) * 2006-06-28 2009-03-27 아스카 세이야쿠 가부시키가이샤 Treatment agent for inflammatory bowel disease
CA2677842C (en) 2007-02-16 2014-09-16 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EA201070143A1 (en) * 2007-07-13 2010-08-30 Аддекс Фарма С.А. NEW HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATRAL RECEPTORS
WO2009063061A2 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2009000904A1 (en) 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
WO2009138386A2 (en) 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
PL2324008T3 (en) 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors
EP2318403B1 (en) * 2008-08-25 2015-12-23 Boehringer Ingelheim International GmbH Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010045764A1 (en) * 2008-10-23 2010-04-29 Lonza Ltd Process for the synthesis of substituted pyrazoles
CN102224142B (en) * 2008-11-21 2015-07-22 拉夸里亚创药株式会社 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
WO2010139673A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP2013503129A (en) * 2009-08-26 2013-01-31 ノバルティス アーゲー Tetra-substituted heteroaryl compounds and their use as MDM2 and / or MDM4 modulators
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
CN102762551A (en) 2009-12-21 2012-10-31 拜尔农作物科学股份公司 Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
MX341728B (en) 2010-01-27 2016-08-30 Nerviano Medical Sciences S R L * Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors.
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CN103260622B (en) * 2010-12-20 2015-05-13 辉瑞大药厂 Novel fused pyridine compounds as casein kinase inhibitors
AR086992A1 (en) 2011-06-20 2014-02-05 Bayer Ip Gmbh TIENILPIRI (MI) DINILPIRAZOLES
EP2744783A1 (en) 2011-08-17 2014-06-25 Boehringer Ingelheim International GmbH Indenopyridine derivatives
UA114490C2 (en) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Heterocyclylpyri(mi)dinylpyrazole as fungicidals
JP6211522B2 (en) 2011-10-06 2017-10-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Heterocyclylpyri (mi) dinylpyrazole
DE102011115525A1 (en) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Two-part bottle packaging device for containing pharmaceutical tablets or capsules, has bottle body and bottle base, where bottle is closed with pressure lock or with pressure lock injected at bottle body or with separate rotary lock
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
PT2782557T (en) 2011-11-23 2018-11-26 Array Biopharma Inc Pharmaceutical formulations
JP6579623B2 (en) 2013-03-15 2019-09-25 ザ・スクリップス・リサーチ・インスティテュート Compounds and methods for inducing cartilage formation
CN105814024B (en) * 2013-12-12 2018-04-17 住友化学株式会社 Aromatic compounds and application thereof
CN104829536B (en) * 2015-05-04 2017-12-29 陕西科技大学 A kind of Phenylpyrazole carboxylic acid compound and its synthetic method for having antitumor activity
EP3303284B1 (en) * 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN112480079B (en) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 Compounds and their use for treating cancer
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
CN1264377A (en) 2000-08-23
SK157899A3 (en) 2000-08-14
NO995695D0 (en) 1999-11-19
OA12981A (en) 2006-10-13
AP1246A (en) 2004-02-07
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
EE9900527A (en) 2000-06-15
JP2002508754A (en) 2002-03-19
IL132991A (en) 2005-11-20
ZA984358B (en) 1999-05-24
EP1000055A1 (en) 2000-05-17
EA003925B1 (en) 2003-10-30
AU754830B2 (en) 2002-11-28
AU7588398A (en) 1998-12-11
NZ501112A (en) 2002-10-25
IL132991A0 (en) 2001-03-19
BG64313B1 (en) 2004-09-30
HUP0001880A3 (en) 2002-03-28
KR20010012854A (en) 2001-02-26
ID22982A (en) 1999-12-23
HUP0001880A2 (en) 2001-03-28
EA199900953A1 (en) 2000-10-30
AU754830C (en) 2004-02-12
IS5257A (en) 1999-11-19
GEP20033053B (en) 2003-08-25
CA2291115A1 (en) 1998-11-26
BR9809147A (en) 2000-08-01
AP9901715A0 (en) 1999-12-31
TR200000235T2 (en) 2000-05-22
BG103964A (en) 2000-08-31

Similar Documents

Publication Publication Date Title
NO995695L (en) Substituted pyrazoles as p38 kinase inhibitors
AP2001002172A0 (en) Substituted pyrazoles as p38 kinase inhibitors
DK0675886T3 (en) Aminomethylene-substituted non-aromatic heterocycles and their use as substance P antagonists
CA2369504A1 (en) Pyrazole compositions useful as inhibitors of erk
BG105177A (en) Novel substituted pyrazole derivatives
IL129409A0 (en) 1-Phenylpyrazole compounds and pharmaceutical compositions containing the same
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
CA2400447A1 (en) Kinase inhibitors
WO2001090071A3 (en) Substituted iminoazines used as herbicides
NO971471L (en) New carboxamides with fungicidal activity
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
CA2298462A1 (en) 2-benzoyl-cyclohexane-1,3-dione as herbicides
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
DE60004340D1 (en) SUBSTITUTED 1,4-DIHYDROINDENO [1,2-C] PYRAZOLE AS INHIBITORS OF TYROSINKINASE
EP0757987A4 (en) Pyrazolecarboxylic acid derivative and plant disease control agent
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
MX9702203A (en) Substituted pyrazolyl-pyrazole derivatives, processes for their preparation and their use as agents with herbicidal action.
WO2001090102A3 (en) 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
NO20022123L (en) Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
WO2003017766A3 (en) Herbicides made from substituted aryl ketones
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
WO2000020399A3 (en) Use of substituted 5-hydroxypyrazoles, novel 5-hydroxypyrazoles, methods for the production thereof and agents containing the same
DK357783D0 (en) 1-PHENYL OR HETEROARYL SUBSTITUTED 1- (5-CHLORPYRID-2-YL) -1-HALOGEN-2- (1,2,4-TRIAZOL-1-YL) ETHANE COMPOUNDS AND THEIR PHARMACEUTICAL OR AGRICULTURAL ADDITIONAL ACCEPTABLE ACCEPTABLE ACCEPTABLE FOR MANUFACTURING THEREOF

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application